amfAR, The Foundation for AIDS Research, is dedicated to ending the global AIDS epidemic through innovative research.
Research

Countdown to a Cure for AIDS

In February 2015, amfAR launched a $100 million investment strategy to support its Countdown to a Cure for AIDS initiative, aimed at developing the scientific basis of a cure by 2020. The strategy represents an unprecedented expansion of amfAR’s research grant making. Structured to provide sustained support for a wide range of studies that advance both emerging and established ideas, the strategy comprises the following key components:

► The amfAR Institute for HIV Cure Research, launched at the end of 2015 at the University of California, San Francisco, will be the cornerstone of amfAR’s cure research efforts and will be supported by a $20 million grant over five years.

► Innovation Grants of up to $200,000 each will enable researchers to test innovative ideas supported by limited preliminary data. The first round of 11 Innovation Grants totaling close to $2 million was awarded in February 2015.

► Impact Grants support the in-depth development of concepts already underpinned by preliminary data showing genuine potential for achieving a cure. In July, amfAR awarded the first three Impact Grants of $2 million each over four years. Researchers in Boston, San Francisco, and Melbourne, Australia, are investigating the ability of combinations of antibodies to kill latently infected cells, pursuing a novel intervention aimed at restoring normal immune function in people with HIV, and exploring whether drugs that block so-called immune checkpoints that have proven effective in treating cancer can also be effective against HIV.

► Investment Grants are aimed at recruiting the experience and expertise of scientists from outside the field of HIV. These $1 million grants will be awarded over a four-year period. Grantees may have expertise in fields such as cancer, neuroscience, or inflammatory disease that can directly inform efforts to cure HIV.

► ARCHE—the amfAR Research Consortium on HIV Eradication—supports collaborative teams of scientists in the U.S. and around the world working on a range of HIV cure strategies. In February 2015, amfAR awarded $1.5 million to three teams of researchers in the U.S., Denmark, and Germany who are testing the ability of the cancer drug Romidepsin, which has been shown to be effective at “shocking” HIV out of hiding, combined with an antibody to eliminate infected cells and thus reduce the size of the persistent HIV reservoir.

Mathilde Krim Fellowships

In October 2014, amfAR awarded an eighth round of Mathilde Krim Fellowships in Basic Biomedical Research, an initiative that provides funding for exceptional young researchers who are new to the field of HIV/AIDS research. The initiative has already achieved spectacular results.

Published Research

Research studies make the greatest impact on the AIDS field and on the broader scientific community when they are published in scientific journals. In the past year, 44 scientific publications resulted from amfAR-funded research.

HIV Cure Summit

In November 2014, amfAR held its first annual HIV Cure Summit at the New York Academy of Sciences, where leading amfAR-funded HIV cure researchers reported on their progress and discussed the scientific challenges that continue to stand in the way of a cure. Topics included attempts to eliminate viral reservoirs with methods including “shock and kill,” which involves reactivating the virus so it can be destroyed; vaccines and other immune-based strategies; and gene and cell therapy.
Think Tank

In March 2015, 12 leading pediatric HIV researchers, immunologists, and other scientists came together in Las Vegas, Nevada, for a second amfAR think tank to discuss progress in the search for a cure for children living with HIV. Participants sought to collectively identify new avenues of investigation that can best build upon recent breakthroughs.

TREAT Asia

amfAR’s TREAT Asia (Therapeutics Research, Education, and AIDS Training in Asia) program is a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV treatments to adults and children across the Asia-Pacific through research, education, and advocacy of evidence-based HIV-related policies. The TREAT Asia Network encompasses 20 adult and 18 pediatric sites throughout the region, which collaborate on a variety of projects. TREAT Asia scientists published 28 publications in peer-reviewed medical journals in fiscal year 2015.

Gathering Critical Information

TREAT Asia pioneered the region’s first adult observational database for HIV/AIDS, which now includes anonymous data collected from approximately 9,000 patients at 21 clinical sites in 12 countries. The information gathered and analyzed through the database informs the development of more effective research and treatment programs and helps define treatment standards specific to HIV/AIDS in Asia. In 2015, TREAT Asia launched a new database called TAHOD-Lite that includes more basic data but from a much larger proportion of the HIV-positive patients seen at participating sites.

A Global Collaboration

TREAT Asia manages the Asia-Pacific section of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), a global collaboration established by the U.S. National Institute of Allergy and Infectious Diseases. TREAT Asia is working with the Thai Red Cross AIDS Research Centre in Bangkok to conduct a Thai component of a new study that aims to develop and validate a standardized tool to better understand treatment adherence among young people.

Improving Care for Children

TREAT Asia’s Pediatric Network includes 18 sites in six countries; these sites share information and best practices in an effort to improve the quality of pediatric care in the region. The TREAT Asia Pediatric HIV Observational Database was modeled on the adult database and includes data from approximately 5,500 pediatric patients.
Adolescent Research

In 2015, TREAT Asia conducted several studies aimed at improving the health and well-being of adolescents living with HIV. Among them was a Thai study, supported by ViiV Healthcare, of whether technology-based interventions can increase adherence to antiretroviral therapy among adolescents.

Expanding Pre-Exposure Prophylaxis (PrEP) in Thailand

In an effort to improve national HIV prevention efforts, the Thai Red Cross AIDS Research Centre, a TREAT Asia network member, and Adam’s Love, Thailand’s leading Internet and social media-based HIV outreach initiative, began working on two groundbreaking efforts to bring oral PrEP to men who have sex with men (MSM) in Thailand. Both projects are supported in part by TREAT Asia.

Exploring Links Between HIV and Cancer

Because MSM living with HIV are twice as likely as those without HIV to develop the anal cancer associated with human papilloma virus (HPV) infection, the Anonymous Clinic of the Thai Red Cross AIDS Research Centre started screening its patients for anal precancers. With amfAR funding, it purchased the high-resolution microscope necessary to diagnose and treat precancerous anal lesions. With support from TREAT Asia and others, three TREAT Asia sites in Indonesia and Malaysia have established similar programs.

Mobilizing HIV-Positive Youth

With support from ViiV Healthcare’s new Positive Action for Adolescents program, TREAT Asia launched a program called Youth ACATA (Asia Community for AIDS Treatment and Advocacy) in an effort to mobilize HIV-positive youth across the region. It held three Youth ACATA workshops for young people living with HIV from Cambodia, Indonesia, Thailand, and Vietnam.

Targeting At-Risk Populations Online

In August 2015, Adam’s Love (see Expanding Pre-Exposure Prophylaxis [PrEP] in Thailand) launched Adam’s Love Taiwan, its fourth country-specific HIV outreach campaign targeting at-risk populations through its unique online edutainment approach that combines educational HIV resources with videos and social media posts from celebrities. Adam’s Love is supported by ViiV and amfAR, and sponsored by the Thai Red Cross AIDS Research Centre.

Education and Advocacy

TREAT Asia continued to publish lay-language articles on AIDS research, policy, and community issues facing the Asia-Pacific region. The articles and educational pieces appear in the TREAT Asia Report, a bimonthly e-newsletter, and on TREAT Asia’s website, www.treatasia.org. TREAT Asia also published a policy brief urging governments, public health authorities, healthcare providers, and civil society in Asia to address persistent gaps in women’s access to reproductive health services, especially for women living with HIV.

Public Policy

Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate AIDS-related public policy. The Foundation works to secure necessary increases
in funding for HIV/AIDS research; implement the U.S. National HIV/AIDS Strategy; expand access to care and treatment; improve prevention; and protect the civil rights of all people affected by HIV/AIDS.

PEPFAR and the Global Epidemic

PEPFAR—the U.S. President’s Emergency Plan for AIDS Relief—is the largest international program responding to the global HIV/AIDS epidemic and the largest commitment one nation has ever made to combat a disease internationally. In 2015, amfAR launched its PEPFAR Country/Regional Operational Plan database, a comprehensive, navigable database of PEPFAR’s planned funding of HIV/AIDS activities from 2007 to 2014. The database is designed to help civil society organizations, ministries of health and finance, researchers, and other stakeholders to access and understand PEPFAR’s programs and priorities at a deeper level than was possible using other platforms.

Addressing HIV/AIDS Among Women

In March 2015, amfAR held a Congressional briefing in Washington, D.C., to illuminate the work that remains to be done to achieve an AIDS-free generation among women and girls in the U.S. and globally. The briefing drew leaders from government, academia, and the nonprofit sector, including House Democratic Leader Nancy Pelosi, Jeannette Kagame, First Lady of Rwanda and cofounder of the Organization of African First Ladies Against HIV/AIDS, and Ambassador Deborah Birx, M.D., U.S. Global AIDS Coordinator.

Shaping the Domestic Response to HIV/AIDS

In July 2015, amfAR issued a report titled Bolstering State Efforts to Implement the National HIV/AIDS Strategy: Key Indicators and Recommendations for Policymakers and Community Stakeholders. The report outlined recommendations for how states across the U.S. can improve their HIV prevention and care responses. It was released to coincide with the White House’s 2015 update to the U.S. National HIV/AIDS Strategy.

HIV and Black Gay Men

In February 2015, amfAR published an issue brief showing that efforts to address the HIV epidemic among black gay men have been consistently inadequate and that immediate steps must be taken to reduce new HIV infections among this underserved population. The brief, titled HIV and the Black Community: Do #Black (Gay) Lives Matter? described the underlying factors contributing to elevated infection rates among black men and provided a list of steps that can be taken to mitigate this persistent racial disparity.

HIV and Injecting Drug Use

A dramatic spike in HIV infections in rural Scott County, Indiana, caused by the sharing of contaminated needles by injecting drug users, underscored the urgent need to expand access to harm reduction programs and syringe exchange in particular. This mode of transmission continues to be a driver of the epidemic in many parts of the world and amfAR has long played a leading role in advocating the use of federal funds to support these lifesaving HIV prevention programs. In the wake of the Indiana outbreak, amfAR CEO Kevin Robert Frost authored an op-ed on the issue for CNN.com and amfAR published a pair of issue briefs outlining the importance of syringe services programs (SSPs) as a highly effective tool in the fight against the spread of HIV and hepatitis C.

In its Harm Reduction and the Global HIV Epidemic report, released in September 2015, amfAR assessed the state of harm reduction worldwide by focusing on the steps that five sample countries—Kenya, Kyrgyzstan, Nigeria, Ukraine, and Vietnam—have, or have not, taken to address the epidemic among people who inject drugs.

Treatment Access

In a policy brief on hepatitis C and drug pricing, amfAR called for structural changes that alter the pricing incentives for pharmaceutical companies in such a way that they cannot charge extortionate prices for their products, however effective they may be. New pharmaceutical breakthroughs have made curing hepatitis C infection easier and more effective, but they have been priced at aggressively high rates that bear no relation to the cost of research and development.

In another issue brief titled Trans-Pacific Partnership: Curbing Access to Medicines Now and in the Future, amfAR strongly opposed the proposed terms of the Trans-Pacific Partnership, warning that expanding existing intellectual property protections could result in a decline in generic competition and an increase in drug costs, while setting an unacceptable precedent for future free trade agreements. Two agreements being negotiated threaten the future availability of affordable generic medicines for diseases such as HIV/AIDS, cancer, tuberculosis, and hepatitis C, and could undermine the global health response in developing countries.
The GMT Initiative

In every corner of the world, gay men, other men who have sex with men, and transgender individuals (collectively, GMT) are disproportionately affected by HIV. Since 2007, amfAR has been advancing efforts to improve prevention for this population, expand access to testing and treatment, and combat stigma and discrimination in hard-hit countries worldwide.

Implementation Science Awards

In 2015, the focus of amfAR’s grant making through the GMT Initiative evolved from the distribution of small grants to community-based organizations to the support of larger implementation science projects aimed at identifying barriers to HIV testing, treatment and care, and studying the impact of innovative HIV service delivery models for GMT in low- and middle-income countries. amfAR awarded $2.6 million over three years to support three such studies.

► Dr. Chris Beyrer of Johns Hopkins University is leading a team of researchers and community-based services (in collaboration with the International HIV/AIDS Alliance Myanmar) in evaluating the effectiveness of promising interventions for GMT in Myanmar, where increased HIV testing and treatment opportunities are becoming available. The researchers are assessing the effectiveness of HIV self-testing, point-of-care CD4 testing, and the use of “peer navigators” familiar with the local health system to help those newly diagnosed gain access to treatment and care.

► In Lima, Peru, Dr. Javier Lama of Asociación Civil Impacta Salud y Educación and his team aim to improve the continuum of care among transgender women by using an innovative model that integrates HIV prevention and treatment services with transgender-affirming medical care.

► And in Bangkok, Thailand, Dr. Nittaya Phanuphak and her team at the Thai Red Cross AIDS Research Centre aim to show how innovative technologies such as GMT-targeted websites using online counseling and support can be utilized to increase rates of HIV testing and referrals to prevention and treatment programs.

Evidence in Action

In 2015, amfAR supported five community-based organizations in Africa and Latin America in evaluating their efforts to improve HIV treatment and care among GMT individuals as part of the GMT Initiative’s Evidence in Action Program, which evaluates the impact of community-based programs with the ultimate goal of implementing the most workable strategies for stopping the spread of HIV/AIDS. Evidence in Action was developed with support from ViiV Healthcare’s Positive Action program and the Elton John AIDS Foundation.

Supporting Young Researchers

amfAR also supported four young researchers from Belize, China, Pakistan, and South Africa undergoing five months of graduate-level public health study at the Center for LGBT Health Research of the Graduate School of Public Health at the University of Pittsburgh. This amfAR HIV Scholars Program aims to strengthen GMT community-based research and responses to HIV, often in areas where little data about HIV among GMT currently exist and where stigma and discrimination deter many GMT from seeking HIV testing and services.

Opposites Attract

In January 2015, amfAR provided support to the Instituto Pesquisa Clinica Evandro Chagas in Rio de Janeiro, Brazil, one of 16 clinical sites participating in the Opposites Attract Study, an ongoing international study that explores the effectiveness of “treatment as prevention” in gay male serodiscordant relationships (one sexual partner is living with HIV and the other is not). The study aims to determine the extent to which HIV incidence is associated with whether an HIV-positive partner is on antiretroviral therapy.

Lessons from the Front Lines

With support from the Arcus Foundation and in collaboration with Global Action for Trans Equality (GATE), amfAR published Lessons From the Front Lines: Trans Health and Rights. The report examined data on access to health services and legal protections for transgender individuals in different settings and detailed how stigma and discrimination combine to create nearly insurmountable challenges for these populations and the organizations that serve them.
Public Information

Through a wide range of communications vehicles and platforms, amfAR disseminates information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences. Through these activities, the Foundation increases awareness of the persistent global public health threat posed by HIV/AIDS and works to combat the stigma associated with HIV that deters many people from getting tested or seeking treatment.

Informing and Educating

amfAR publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policymakers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for AIDS. Publications include Innovations, a newsletter published twice a year and distributed to more than 45,000 people, and a monthly e-mail newsletter distributed to nearly 100,000. Featuring news, interviews, and other original content, the Foundation’s website—www.amfar.org—attracts an average 30,000 visitors per month.

Social Media

amfAR vigorously expanded its presence in the social media arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation regularly added content to its Facebook page and live-tweeted and posted images on Instagram from fundraising and program events. amfAR has 67,000 likes on Facebook, 35,400 Twitter followers, and more than 81,000 Instagram followers.

Media Outreach

amfAR works closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of AIDS-related press coverage. Articles and reports involving amfAR—many of which included interviews with amfAR staff and spokespeople—were carried in numerous media outlets, including the New York Times, the Wall Street Journal, the Washington Post, and the Huffington Post, and news agencies such as The Associated Press, CNN, Bloomberg News, and Reuters.

Enlisting the Help of Public Figures

amfAR’s public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation’s mission. Support from prominent public figures began with the late Dame Elizabeth Taylor, amfAR’s Founding International Chairman, and others have followed in her footsteps. amfAR is profoundly grateful for the continuing steadfast support of Global Campaign Chair Sharon Stone.

Other celebrity supporters included Andrea Bocelli, Adrien Brody, Naomi Campbell, Dean and Dan Caten, Cher, Andy Cohen, Anderson Cooper, Laverne Cox, Miley Cyrus, Rosario Dawson, Leonardo DiCaprio, Whoopi Goldberg, Iman, Scarlett Johansson, amfAR Ambassador Milla Jovovich, Harvey Keitel, Heidi Klum, Eva Longoria, Lea Michele, Kylie Minogue, Kate Moss, Ryan Murphy, Gwyneth Paltrow, Eddie Redmayne, Rihanna, Michelle Rodriguez, Chris Rock, Carine Roitfeld, Brooke Shields, Mario Testino, Robin Thicke, Justin Timberlake, Chris Tucker, Dita Von Teese, Harvey Weinstein, and amfAR Ambassador Michelle Yeoh.
<table>
<thead>
<tr>
<th>Projects Listed Below</th>
<th>Funding Period</th>
<th>Funding Amount</th>
<th>Institution</th>
<th>Principal Investigator</th>
<th>Project Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>The size and maintenance of the latent HIV reservoir in T-cell subsets</td>
<td>Through September 30, 2015</td>
<td>$180,000</td>
<td>The Rockefeller University, New York, NY</td>
<td>Gerd Fätkenheuer, MD</td>
<td>Understanding the role of the HIV Envelope in viral persistence and latency</td>
</tr>
<tr>
<td>Interleukin-21 therapy to reduce HIV persistence</td>
<td></td>
<td>$179,999</td>
<td>Emory University Atlanta, GA</td>
<td>Michel Nussenzweig, MD, PhD</td>
<td>Molecular characterization of non-induced proviruses</td>
</tr>
<tr>
<td>Cell-Intrinsic Immune Modulation of HIV Latency</td>
<td></td>
<td>$180,000</td>
<td>Blood Systems, Inc. San Francisco, CA</td>
<td>Benjamin Burwitz, PhD</td>
<td>Impact of sirolimus (Rapamycin) on HIV-1 Persistence and Immune Function</td>
</tr>
<tr>
<td>Creation of transgenic CCR5 knockout Mauritian cynomolgus macaques</td>
<td></td>
<td>$179,944</td>
<td>Aarhus University Hospital Aarhus, Denmark</td>
<td>Stylianos Bournazos, PhD</td>
<td>Impact of everolimus on HIV persistence post kidney or liver transplant</td>
</tr>
<tr>
<td>Combining CTL with TLR-2 Agonists to Eradicate Natural HIV Reservoirs</td>
<td></td>
<td>$180,000</td>
<td>University of Nebraska-Lincoln Lincoln, NE</td>
<td>Charles Wood, PhD</td>
<td>CNS as Reservoir for Subtype C HIV-1 Infection</td>
</tr>
<tr>
<td>Epigenetic mechanisms of HIV transcriptional activation</td>
<td></td>
<td>$180,000</td>
<td>Dana-Farber Cancer Institute Boston, MA</td>
<td>Alon Herschhorn, PhD</td>
<td>Regulation of the conformational transitions in HIV-1 envelope glycoprotein</td>
</tr>
<tr>
<td>Fc effector activity of anti-HIV-1 broadly neutralizing antibodies</td>
<td></td>
<td>$5,000</td>
<td>Umeå University Umeå, Sweden</td>
<td>Lucie Etienne, PhD</td>
<td>Fc effector activity of anti-HIV-1 broadly neutralizing antibodies</td>
</tr>
<tr>
<td>A3G induced viral evolution</td>
<td></td>
<td>$150,000</td>
<td>Veterans Medical Research Foundation San Diego, CA</td>
<td>Marta Massanella, PhD</td>
<td>A3G induced viral evolution</td>
</tr>
<tr>
<td>Host factors that protect humans and great apes against lentiviruses</td>
<td></td>
<td>$56,171</td>
<td>Institut National de la Santé et de la Recherche Médicale, INSERM Bron, France</td>
<td>Lucie Etienne, PhD</td>
<td>Host factors that protect humans and great apes against lentiviruses</td>
</tr>
<tr>
<td>Regulation of Env-specific germinal center B cells</td>
<td></td>
<td>$12,000</td>
<td>Cold Spring Harbor Laboratory Cold Spring Harbor, NY</td>
<td>Alon Herschhorn, PhD</td>
<td>Regulation of Env-specific germinal center B cells</td>
</tr>
<tr>
<td>The size and maintenance of the latent HIV reservoir in T-cell subsets</td>
<td></td>
<td>$180,000</td>
<td>Fred Hutchinson Cancer Research Center Seattle, WA USA</td>
<td>Alon Herschhorn, PhD</td>
<td>Understanding the role of the HIV Envelope in viral persistence and latency</td>
</tr>
<tr>
<td>Interleukin-21 therapy to reduce HIV persistence</td>
<td></td>
<td>$179,999</td>
<td>Emory University Atlanta, GA</td>
<td>Michel Nussenzweig, MD, PhD</td>
<td>A3G induced viral evolution</td>
</tr>
<tr>
<td>Cell-Intrinsic Immune Modulation of HIV Latency</td>
<td></td>
<td>$180,000</td>
<td>Blood Systems, Inc. San Francisco, CA</td>
<td>Benjamin Burwitz, PhD</td>
<td>Impact of sirolimus (Rapamycin) on HIV-1 Persistence and Immune Function</td>
</tr>
<tr>
<td>Creation of transgenic CCR5 knockout Mauritian cynomolgus macaques</td>
<td></td>
<td>$179,944</td>
<td>Aarhus University Hospital Aarhus, Denmark</td>
<td>Stylianos Bournazos, PhD</td>
<td>Impact of everolimus on HIV persistence post kidney or liver transplant</td>
</tr>
<tr>
<td>Combining CTL with TLR-2 Agonists to Eradicate Natural HIV Reservoirs</td>
<td></td>
<td>$180,000</td>
<td>University of Nebraska-Lincoln Lincoln, NE</td>
<td>Charles Wood, PhD</td>
<td>CNS as Reservoir for Subtype C HIV-1 Infection</td>
</tr>
<tr>
<td>Epigenetic mechanisms of HIV transcriptional activation</td>
<td></td>
<td>$180,000</td>
<td>Dana-Farber Cancer Institute Boston, MA</td>
<td>Alon Herschhorn, PhD</td>
<td>Regulation of the conformational transitions in HIV-1 envelope glycoprotein</td>
</tr>
<tr>
<td>Fc effector activity of anti-HIV-1 broadly neutralizing antibodies</td>
<td></td>
<td>$5,000</td>
<td>Umeå University Umeå, Sweden</td>
<td>Lucie Etienne, PhD</td>
<td>Fc effector activity of anti-HIV-1 broadly neutralizing antibodies</td>
</tr>
<tr>
<td>A3G induced viral evolution</td>
<td></td>
<td>$150,000</td>
<td>Veterans Medical Research Foundation San Diego, CA</td>
<td>Marta Massanella, PhD</td>
<td>A3G induced viral evolution</td>
</tr>
</tbody>
</table>
2015 TREAT ASIA GRANTS AND AWARDS

1Supported by National Institutes of Health cooperative agreement number U01AI069907 with funds from the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Cancer Institute.

2Supported by National Institutes of Health grant number R01HD073972 funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

3Supported with funds provided by the AIDS Life Association.

4Supported with funds provided by the Open Society Foundations.

5Supported with funds provided by Viiv Healthcare.

6Supported with funds provided by the Mel Wolf Foundation.

AUSTRALIA

AUSTRALIA HIV OBSERVATIONAL DATABASE (AHOD) SITES

O’Brien Street Practice
Adelaide, South Australia
William Donohue, MBBS
$1,500

Sexual Health and HIV Service In Metro North
Brisbane, Queensland
Diane Rowling, MBBS, MTH, Fi(PHM), RACP, FACbSHM
$4,650

Cairns Sexual Health Service
Cairns, Queensland
Darren Russell, MD
$4,950

RPA Sexual Health Clinic
Camperdown, New South Wales
David Templeton, PhD
$675

Monash Health - Clayton
Clayton, Victoria
Ian Wooley, MBBS, FRACP
$3,900

D.A. Ellis Pty., Ltd.
Coffs Harbour, New South Wales
David Ellis, MBBS
$975

East Sydney Doctors
Darlington, New South Wales
David Baker, BHB
$7,050

Holdsworth House Medical Practice
Darlington, New South Wales
Mark Bloch, MD
$6,000

St. Vincent’s Hospital Sydney
Darlington, New South Wales
David A. Cooper, MD
$5,250

Taylor Square Private Clinic
Darlington, New South Wales
Robert Finlayson, MBBS
$5,250

Northern Territory Dept of Health & Community Services, Sexual Health & Blood Borne Virus Program
Darwin, Northern Territory
Manoji Gunathilake, MD, MBBS, DFSRHO
$900

Gladstone Road Medical Centre
Highgate Hill, Queensland
David Orth, MBBS, DIP Ven
$5,400

Nepean Blue Mountains Local Health District, Blue Mountains Sexual Health and HIV Clinic
Katoomba, New South Wales
Eva Jackson, MBBS, FACbSHM
$1,050

Nepean Blue Mountains Local Health District, Nepean Sexual Health Clinic
Kingswood, New South Wales
Eva Jackson, MBBS, FACbSHM
$750

Sexual Health and AIDS Services (SHAIDS)
Lismore, New South Wales
David Smith, MBBS, DipVen, FACbSHM, GrapDip BA
$5,850

Melbourne Sexual Health Centre
Clayton, Victoria
Tim Read, MBBS, DipVen, FRACGP, FACbSHM, EpDip
$4,650

Victorian HIV Service, Infectious Diseases
Department, The Alfred Hospital
Melbourne, Victoria
Jennifer Hoy, MBBS
$5,925

Sunshine Coast Hospital and Health Service
Nambour West, Queensland
David Sowden, MBBS, FRACP, PhD
$3,900

Northside Clinic (Vic) Pty Ltd
North Fitzroy, Victoria
Richard Moore, MBBS, FRACGP, DipOb, DipVen
$7,500

Royal Perth Hospital
Perth, Western Australia
David Nolan, MBBS, FRACP, PhD
$5,250

Prahran Market Clinic Pty Ltd
Prahran, Victoria
Norman Roth, MBBS FACbSHM
$5,825

Sydney Sexual Health Centre, Sydney Hospital
Sydney, New South Wales
Caroline Thng, MBBS, MRCP
$4,500

Hunter New England Health, Clinic 468, Tamworth Sexual Health Service
Tamworth NEMSC, New South Wales
Nathan Ryder, MD
$900

Illawarra Shoalhaven Local Health District
Warranowong, New South Wales
Katherine Brown, MD
$1,350

University of New South Wales
Sydney, New South Wales
Matthew G. Law, PhD

Asia-Pacific HIV Research Collaboration: TREAT Asia HIV Observational Database and Australia HIV Observational Database
$361,314

Asia-Pacific HIV Research Collaboration: Cancer Studies
$60,686

Asia-Pacific HIV Research Collaboration: TREAT Asia Pediatric HIV Observational Database
$182,262

CAMBODIA

National Center for HIV/AIDS, Dermatology & STDs / Cambodia National Institute of Public Health
Phnom Penh
Ly Penh Sun, MD, MSc
TREAT Asia HIV Observational Database (TAHOD)
$20,000

TREAT Asia Pediatric HIV Observational Database (TApHOD)
$25,000

National Pediatric Hospital
Phnom Penh
Ung Vibol, MD
Training for early disclosure for children and adolescents in National Pediatric Hospital
$10,000

New Hope for Cambodian Children
Killeen, TX
John Tucker
Our Village
$50,000

CHINA

Beijing Ditan Hospital
Beijing
Fuie Zhang, MD
TREAT Asia HIV Observational Database (TAHOD)
$16,000

Queen Elizabeth Hospital
Hong Kong
Man Po Lee, MBBS
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$23,660

INDIA

Johns Hopkins University at B.J. Medical College and Sassoon General Hospital
Pune
Vidy Mave, MD, MPH
Epidemiology of HIV/AIDS and associated comorbidities in a public antiretroviral treatment (ART) clinic in Pune, India
$304,185
Promoting adherence and nutritional care for Children with HIV
$12,776^\dagger$

**JAPAN**

**National Center for Global Health and Medicine**

Tokyo
Shinichi Oka, MD
TREAT Asia HIV Observational Database (TAHOD)
$16,000^\dagger$

**INDONESIA**

Cipto Mangunkusumo General Hospital

Jakarta
Nia Kurniati, MD
TREAT Asia Pediatric HIV Observational Database (TAPeHOD)
$5,000^\dagger$

Bone health and vitamin D status among perinatally HIV-infected Asian children with virological suppression
$13,065^\dagger$

Evy Yunihastuti, MD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$22,750^\dagger$

Effectiveness and tolerability of HCV treatment in HIV co-infected patients: Treatment
$35,897^\dagger$

**Indonesia AIDS Coalition**

Jakarta
Aditya Wardhana
Creating joint action plans to address the needs of Children Living with HIV
$9,047^\dagger$

**Sanglah Hospital, Udayana University School of Medicine**

Denpasar, Bali
Tuti Parwati Merati, MD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$23,040^\dagger$

**Sanglah Hospital, Udayana University School of Medicine**

Denpasar, Bali
Ketut Dewi Kumara Wati, MD
TREAT Asia Pediatric HIV Observational Database (TAPeHOD)
$7,500^\dagger$

**Spiritia Foundation**

Jakarta
Meirinda Sebayang
Indonesia pediatric HIV program assessment
$9,986^\dagger$

**PHILIPPINES**

Asian Foundation for Tropical Medicine, Inc.
Muntinlupa City
Rossana Ditangco, MD
National HIV Testing Week Campaign and International AIDS Candlelight Memorial, Philippines
$3,351^\dagger$

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$23,410^\dagger$

**SINGAPORE**

Tan Tock Seng Hospital

Singapore
Oon Tek Ng, MBBS, MRC
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$16,000^\dagger$

**SOuth KOREA**

Yonsei University College of Medicine

Seoul
Jun Yong Choi, MD, PhD
TAHOD Low-Intensity Transfer (TAHOD LITE) including NCD Data
$24,590^\dagger$

**TAIWAN**

Taipei Veterans General Hospital

Taipei City
Wing-Wai Wong, MD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$24,590^\dagger$

**THAILAND**

Chiang Mai University - Research Institute for Health Sciences

Chiang Mai
Romanee Chaiwarith, MD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$25,240^\dagger$

Tavitiya Sudjaritruk, MD, ScM
Chiang Mai University - Research Institute for Chronic Illnesses & Cancer in PLHA
$5,000^\dagger$

Using the Taiwan National Health Insurance Database to Study the Associations between Chronic Illnesses & Cancer in PLHA
$39,397^\dagger$
Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI
$4,650\textsuperscript{1}$

Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia
$63,613\textsuperscript{1}$

Pacharee Kantipong, MD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$15,460\textsuperscript{1}$

HIV-NAT / Thai Red Cross AIDS Research Centre
Bangkok
Praphan Phanuphak, MD, PhD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$22,890\textsuperscript{1}$

Examining the prevalence rate and determinants of frailty in the HIV positive and negative Thai populations
$30,873\textsuperscript{1}$

Torsak Bunupuradah, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
$15,000\textsuperscript{1}$

Bone health and vitamin D status among perinatally HIV-infected Asian children with virological suppression
$110,282\textsuperscript{1}$

Changes in metabolic and inflammatory markers in HIV-positive adolescents using hormonal contraception
$10,350\textsuperscript{1}$

Promoting Mental Health Interventions for Perinatally HIV-Infected Thai Youth: Expanded Scope
$6,500\textsuperscript{1}$

Stephen Kerr, PhD
Prospective validation of an adherence monitoring tool among HIV-infected children and adolescents at iDea sites
$10,814\textsuperscript{1}$

Nittaya Phanuphak, MD, PhD
Identifying Biomarkers of Anal Intraepithelial Neoplasia in Thai MSM
$95,000\textsuperscript{1}$

Study on anal HPV infection and anal intraepithelial neoplasia among MSM in Indonesia, Malaysia, and Thailand
$34,646\textsuperscript{1}$

Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia (central lab & data manager)
$249,357\textsuperscript{2}$

HIV-HPV Research in Asia and the Pacific Meeting
$20,619\textsuperscript{1}$

Wasana Prasitsuebsai, MD, MPH
Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI
$5,775\textsuperscript{1}$

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI (data mgmt center)
$8,000\textsuperscript{1}$

Study Site: Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia
$80,223\textsuperscript{3}$

Coordinating Center: Prospective Monitoring of Second-line Antiretroviral Therapy Failure and Resistance in Children
$46,467\textsuperscript{3}$

TASER-Px: Prospective Monitoring of Second-line Antiretroviral Therapy Failure and Resistance in Children
$13,000\textsuperscript{3}$

Kiat Ruxrunthang, MD
Effectiveness and tolerability of HCV treatment in HIV co-infected patients: Treatment
$48,412\textsuperscript{3}$

Thai Red Cross AIDS Research Centre
Bangkok
Nittaya Phanuphak, MD, PhD
Strengthening skills and qualifications of HRA clinicians in the Asia-Pacific region
$42,600\textsuperscript{3}$

eHealth interventions to improve treatment adherence and retention in care among HIV-positive young Thai MSM
$44,993\textsuperscript{3}$

Mahidol University Faculty of Medicine, Siriraj Hospital
Bangkok
Kulkanya Chokephaibulkit, MD
TASER-Px: Prospective Monitoring of Second-line Antiretroviral Therapy Failure and Resistance in Children
$8,500\textsuperscript{3}$

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI
$7,236\textsuperscript{1}$

Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia
$66,216\textsuperscript{1}$

Ramathibodi Hospital, Mahidol University
Bangkok
Sassiyop Kiertiburanakul, MD, MHS
TASER-Px: Prospective Monitoring of Second-line Antiretroviral Therapy Failure and Resistance in Children
$20,000\textsuperscript{3}$

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI
$7,236\textsuperscript{1}$

Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia
$66,216\textsuperscript{1}$

Srinagarind Hospital, Khon Kaen University
Khon Kaen
Pagakrong Lumbiganon, MD
TASER-Px: Prospective Monitoring of Second-line Antiretroviral Therapy Failure and Resistance in Children
$20,000\textsuperscript{3}$

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI
$5,150\textsuperscript{1}$

Vietnam Network of People Living with HIV (VNP+)
Hanoi
Do Dang Dong
Strengthen advocacy on HCV Diagnosis, Care and Treatment
$2,000\textsuperscript{1}$

VIETNAM

Bach Mai Hospital
Hanoi
Pham Thi Thanh Thuy, MD, PhD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$23,070\textsuperscript{1}$

Children's Hospital 1
Ho Chi Minh City
Truong Huu Khanh, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
$25,000\textsuperscript{1}$

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI
$8,500\textsuperscript{3}$

TASER-Px: Prospective Monitoring of Second-line Antiretroviral Therapy Failure and Resistance in Children
$14,000\textsuperscript{3}$

Thoa Kim Le Phan, MD
Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia
$9,548\textsuperscript{3}$

Children's Hospital 2
Ho Chi Minh City
Do Chau Viet, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
$20,000\textsuperscript{3}$

Huong Vuong Hospital
Ho Chi Minh City
Dang Le Dung Hanh, MD, MA
Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia
$15,598\textsuperscript{3}$

National Hospital of Pediatrics
Hanoi
Nguyen Van Lam, MD, MSc
TREAT Asia Pediatric HIV Observational Database (TApHOD)
$20,000\textsuperscript{3}$

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI
$4,200\textsuperscript{1}$

TASER-Px: Prospective Monitoring of Second-line Antiretroviral Therapy Failure and Resistance in Children
$8,500\textsuperscript{3}$

National Hospital of Tropical Diseases
Hanoi
Nguyen Van Kinh, MD, PhD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$23,230\textsuperscript{1}$

Effectiveness and tolerability of HCV treatment in HIV co-infected patients: Treatment
$32,965\textsuperscript{3}$

Vietnam Network of People Living with HIV (VNP+)
Hanoi
Do Dang Dong
Strengthen advocacy on HCV Diagnosis, Care and Treatment
$2,000\textsuperscript{1}$
All projects listed below were awarded amfAR funding for the period October 1, 2014, through September 30, 2015.

**GMT IMPLEMENTATION SCIENCE RESEARCH GRANTS**

**Continuum of Care Innovations for GMT in Burma/Myanmar**
Principal Investigator: Chris Beyrer, MD, MPH
Johns Hopkins University
Baltimore, MD
$899,887

**Gender-Affirmative Transgender Care to Improve the HIV Treatment Cascade**
Principal Investigator: Javier Lama, MD, MPH
Asociación Civil Impacta Salud y Educación
Lima, Peru
$876,684

**Innovative strategy to offer online Test and Treat services for Thai MSM**
Principal Investigator: Nittaya Phanuphak, MD, PhD
Thai Red Cross AIDS Research Centre
Bangkok, Thailand
$900,000

**GLOBAL LUBRICANT ACCESS MOBILIZATION AWARDS**

**GLAM: CNET**
Project Director: Stephen Diaz
Collaborative Network of Persons Living with HIV (C-NET+)
Belize City, Belize
$5,000

**GLAM: ALFIL**
Project Director: Ricardo Erazo
Asociación ALFIL
Quito, Ecuador
$5,000

**GLAM: Grupo Genesis Panama Positivo**
Project Director: Israel Ned Gill Smith
Grupo Génesis Panamá Positivo (GGP+)
Panamá, Panamá
$5,000

**GLAM: Red Trebol**
Project Director: Pamela Valenzuela
Mesa De Trabajo Nacional
Cochabamba, Bolivia
$5,000

**GENERAL GMT INITIATIVE GRANTS AND AWARDS**

**Opposites Attract Study Site**
Site Principal Investigator: Beatriz Grinsztejn, MD, PhD
Fiotec - Foundation for Scientific and Technological Development in Health, Instituto de Pesquisa Clínica Evandro Chagas
Rio de Janeiro, Brazil
$96,398

**A Training Program for HIV Research among MSM in Developing World Settings**
Project Director: Ronald D. Stall, PhD, MPH
University of Pittsburgh
Pittsburgh, PA
$169,804

**2015 PUBLIC POLICY AWARDS**

The projects listed below were awarded during the period October 1, 2014, through September 30, 2015.

1 Funded with support from the Open Society Foundations
2 Funded with support from the MAC AIDS Fund

**UNITED STATES**

**Implementation of Electronic Medical Record System**
Project Director: Ron Simmons, PhD
Us Helping Us - People Into Living, Inc.
Washington, DC
$4,875

**Harm Reduction Services and Overdose Prevention Advocacy in Puerto Rico**
Project Director: Rafael Torruella, PhD
Intercambios Puerto Rico
Fajardo, Puerto Rico
$20,000

**INTERNATIONAL**

**Meaningful Engagement of People who Use Drugs (PUD) in Removing Legal Barriers towards access to antiretroviral treatment**
Project Director: Edo Agustian
Persaudaraan Korban Napza Indonesia (PKNI)
Jakarta, Indonesia
$20,000

**Advocating for Human rights and access to health services for People Who Use Drugs (PWUD)**
Project Director: Happy Leonard Assan
Tanzania network for people who use drugs
Dar-es-salaam, Tanzania
$10,000

**Project ACE**
Project Director: Shaun Shelly
TB/HIV Care Association
Cape Town, South Africa
$19,466

**Qualitative Assessment of Budget Development and the Improvement of Health Outcomes**
Project Director: Nhlanhla Ndlovu
Centre for Economic Governance and AIDS in Africa
Howick, South Africa
$39,945

---

2015 COMMUNITY OUTREACH AWARDS

**Andrea Bocelli Foundation-St. Damien Pediatric Hospital, Haiti**
Charities Aid Foundation of America
Alexandria, VA USA
$301,163

**The Learning Resource**
Museum of AIDS in Africa
Johannesburg, Gauteng South Africa
$25,000
### Financial Highlights
For the year ended September 30, 2015

#### Public Support and Revenue

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public support</td>
<td>$7,142,007</td>
</tr>
<tr>
<td>Special events</td>
<td>24,033,779</td>
</tr>
<tr>
<td>Planned giving</td>
<td>5,095,713</td>
</tr>
<tr>
<td>Government funding</td>
<td>10,220,999</td>
</tr>
<tr>
<td>Investment income and other revenue</td>
<td>117,700</td>
</tr>
<tr>
<td><strong>Total public support and revenue</strong></td>
<td><strong>$46,610,198</strong></td>
</tr>
</tbody>
</table>

#### Expenses

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$15,282,648</td>
</tr>
<tr>
<td>TREAT Asia</td>
<td>5,820,593</td>
</tr>
<tr>
<td>GMT Initiative</td>
<td>2,365,247</td>
</tr>
<tr>
<td>Public Policy</td>
<td>2,045,870</td>
</tr>
<tr>
<td>Public Information</td>
<td>4,259,732</td>
</tr>
<tr>
<td></td>
<td><strong>Total program services</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fundraising</td>
<td>5,653,227</td>
</tr>
<tr>
<td>Management and general</td>
<td>2,454,606</td>
</tr>
<tr>
<td><strong>Total supporting services</strong></td>
<td><strong>$8,107,833</strong></td>
</tr>
</tbody>
</table>

**Total expenses**                       **$37,881,923**

**Change in net assets**                  **$8,728,275**

**Net assets, beginning of year**        **44,310,347**

**Net assets, end of year**               **$53,038,622**

### Statement of Financial Position

#### Assets

<table>
<thead>
<tr>
<th>Asset</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and investments</td>
<td>$58,377,633</td>
</tr>
<tr>
<td>Accounts receivable, net</td>
<td>7,557,420</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>3,027,106</td>
</tr>
<tr>
<td>Fixed assets, net</td>
<td>2,288,934</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$71,251,093</strong></td>
</tr>
</tbody>
</table>

#### Liabilities

<table>
<thead>
<tr>
<th>Liability</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$3,435,700</td>
</tr>
<tr>
<td>Grants and fellowships payable, net</td>
<td>3,049,552</td>
</tr>
<tr>
<td>Deferred support and refundable advances</td>
<td>10,067,061</td>
</tr>
<tr>
<td>Other long-term liabilities</td>
<td>1,660,158</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>$18,212,471</strong></td>
</tr>
</tbody>
</table>

**Total net assets**                       **$53,038,622**

**Total liabilities and net assets**       **$71,251,093**
Expenses

- Fundraising: $5,653,227
- Management and general: $2,454,606
- Program: $29,774,090

Total: $37,881,923

Program Expenses

- Research: $15,282,648
- TREAT Asia: $5,820,593
- GMT Initiative: $2,365,247
- Public Policy: $2,045,870
- Public Information: $4,259,732

Total: $29,774,090
BOARD OF TRUSTEES
Fiscal year 2015

Chairman of the Board
Kenneth Cole
Chairman
Kenneth Cole Productions
New York, NY

Founding Chairman
Mathilde Krim, Ph.D.
Adjunct Professor
Mailman School of Public Health
Columbia University
New York, NY

Vice Chairman
Patricia J. Matson
Senior Vice President, Communications (ret.)
ABC, Inc.
New York, NY

Treasurer
Wallace Sheft, C.P.A.
Partner (ret.)
Sheft & Co.
Westbury, NY

Secretary
Mervyn F. Silverman, M.D., M.P.H.
President
Mervyn F. Silverman Associates
Crockett, CA

TRUSTEES

Arlen H. Andelson
Andelson Properties
Los Angeles, CA

Harry Belafonte
President
Belafonte Enterprises, Inc.
New York, NY

David Bohnett
Chairman
Bohnett Foundation
Beverly Hills, CA

Zev Braun
President and CEO
Braun Entertainment Group, Inc.
Beverly Hills, CA

Jonathan S. Canno
New York, NY

Donald A. Capoccia
Managing Principal
BFC Partners
Brooklyn, NY

R. Martin Chavez, Ph.D.
Chief Information Officer
The Goldman Sachs Group, Inc.
New York, NY

Jane B. Eisner
President
The Eisner Foundation
Bel Air, CA

T. Ryan Greenawalt
Managing Director
Ramirez & Co.
President
Harrison Street Productions
New York, NY

Regan Hofmann
Policy Officer
Washington Liaison Office
UNAIDS
Washington, D.C.

Michael J. Klingensmith
CEO and Publisher
Minneapolis Star Tribune
Minneapolis, MN

Kevin McClatchy
Chairman of the Board
The McClatchy Company
Ligonier, PA

Michele V. McNeill, Pharm.D.
Chairman
McNeill Family Foundation
Sarasota, FL

Edward L. Milstein
Co-Chairman
Milstein Brothers and Capital Partners
New York, NY

Cindy D. Rachofsky
Philanthropist
Dallas, TX

Vincent A. Roberti
Chairman, Roberti Global
Washington, D.C.

Bill Roedy
London, UK

Raymond F. Schinazi, Ph.D., D.Sc.
Frances Winship Walters Professor
Director, Laboratory of Biochemical Pharmacology
Emory University
Decatur, GA

Alan D. Schwartz
Executive Chairman
Guggenheim Partners, LLC
New York, NY

Diana L. Taylor
Vice Chair
Solera Capital, LLC
New York, NY

TRUSTEE EMERITUS

Arthur J. Ammann, M.D.
President, Global Strategies for HIV Prevention
Clinical Professor of Pediatrics
University of California, San Francisco
San Francisco, CA

IN MEMORIAM

Dame Elizabeth Taylor
Founding International Chairman

Sheldon W. Andelson, Esq.
Arnold W. Klein, M.D.
Mrs. Albert D. Lasker
Jonathan M. Mann, M.D., M.P.H.
Maxine Mesinger
Pauline Phillips
Natasha Richardson
Allan Rosenberg, M.D.
Peter Scott, Esq.
Tom Stoddard
Joel D. Weisman, D.O.

SPECIAL APPOINTMENTS

Global Campaign Chair
Sharon Stone

Global Fundraising Chairman
Milutin Gatsby

amfAR AMBASSADORS

Cheyenne Jackson
Janet Jackson
Milla Jovovich
Liza Minnelli
Michelle Yeoh

COMMITTEES OF THE BOARD OF TRUSTEES

Executive
Kenneth Cole, Chair
Mathilde Krim, Ph.D.
Patricia J. Matson

Audit
Wallace Sheft, C.P.A., Chair
R. Martin Chavez, Ph.D.

Board Development
Donald A. Capoccia, Co-Chair
Patricia J. Matson, Co-Chair
Arlen Andelson
Bill Roedy

Communications/Social Media/Marketing
Regan Hofmann, Chair
Kenneth Cole
T. Ryan Greenawalt
Patricia J. Matson
Kevin McClatchy
Vincent A. Roberti
Bill Roedy

Compensation and Organizational Development
John C. Simons, Chair
Michael J. Klingensmith
Kevin McClatchy
**PROGRAM ADVISORY COUNCIL**

Mervyn F. Silverman, M.D., M.P.H. (Chairman)
President
Mervyn F. Silverman Associates
Crockett, CA

Judith D. Auerbach, Ph.D.
Science and Policy Consultant and Professor
School of Medicine
University of California, San Francisco

David Bloom, Ph.D.
Clarence James Gamble Professor of Economics
and Demography
Department of Global Health and Population
Harvard School of Public Health
Boston, MA

Tim Brown, Ph.D.
Senior Fellow
The East-West Center
Honolulu, HI

Daniel Douek, M.D., Ph.D.
Chief, Human Immunology Section
Vaccine Research Center
National Institute of Allergy and Infectious
Diseases
National Institutes of Health

Daria J. Hazuda, Ph.D.
Vice President, Scientific Affairs for Infectious
Disease
Merck & Company, Inc.
West Point, PA

Kenneth Hugh Mayer, M.D.
Infectious Disease Attending & Director of HIV
Prevention Research
Beth Israel Deaconess Medical Center

Professor of Medicine
Harvard Medical School

Medical Research Director, Co-Chair
The Fenway Institute/Fenway Health

Mario Stevenson, Ph.D.
Professor of Medicine
Chief, Division of Infectious Diseases
University of Miami Leonard M. Miller School of
Medicine

Jeffrey L. Sturchio, Ph.D.
Senior Partner
Rabin Martin
New York, NY

visiting scholar
The Institute for Applied Economics, Global Health
and the study of Business Enterprise
Johns Hopkins University

Member
The Council on Foreign Relations
Washington, D.C.

Phyll Wilson
Chief Executive Officer and President
The Black AIDS Institute
Los Angeles, CA

**MANAGEMENT GROUP**

Kevin Robert Frost
Chief Executive Officer

Anthony Ancona
Vice President and Director, Human Resources

Susan J. Blumenthal, M.D., M.P.A.
Senior Policy and Medical Advisor

Bradley Jensen
Chief Financial Officer

Rowena Johnston, Ph.D.
Vice President and Director, Research

Jeffrey Laurence, M.D.
Senior Scientific Consultant for Programs

John F. Logan, Ph.D., J.D.
Vice President and General Counsel

Gregorio Millett, M.P.H.
Vice President and Director, Public Policy

Eric Muscatell
Vice President, Development

AnnMari Shannahan
Vice President, Public Information

Annette Sohn, M.D.
Vice President and Director, TREAT Asia

**Gail Skowron, M.D.**
Professor of Medicine
Boston University School of Medicine

Serena Spudich, M.D., M.A.
Associate Professor of Neurology
Division Chief, Neurological Infections and
Global Neurology
Department of Neurology
Yale School of Medicine

Leonidas Stamatakos, Ph.D.
Member
Fred Hutchinson Cancer Research Center
Vaccine and Infectious Disease Division
Immunology and Vaccine Development Program
Seattle, WA

Mario Stevenson, Ph.D.
Professor of Medicine
Chief, Division of Infectious Diseases
University of Miami Leonard M. Miller School of
Medicine

Susana Valente, Ph.D.
Associate Professor
Department of Immunology and Microbial
Sciences
The Scripps Research Institute

Barbara Visscher, M.D., Dr.P.H.
Professor of Epidemiology
University of California, Los Angeles

David Vlahov PhD, RN
Professor of Nursing,
Epidemiology, and Biostatistics
University of California, San Francisco

David J. Volsky, Ph.D.
Professor of Medicine and Pathology
Icahn School of Medicine at Mt. Sinai

Director of Molecular Virology Laboratory
Department of Medicine
Mount Sinai St. Luke’s and Roosevelt Hospitals

Steven S. Witkin, Ph.D.
Professor of Immunology
Department of Obstetrics and Gynecology
Weill Cornell Medical College

Peter R. Wolfe, M.D.
Associate Clinical Professor
David Geffen School of Medicine
University of California, Los Angeles

Steven Wolinsky, M.D.
Professor
Medicine/Infectious Diseases
Feinberg School of Medicine
Northwestern University

Richard T. Wyatt, Ph.D.
Professor of Immunology
IAVI Center for Neutralizing Antibodies
The Scripps Research Institute

Jerome Zack, Ph.D.
Professor
Department of Medicine
David Geffen School of Medicine
University of California, Los Angeles